Latest News
Web Date: April 5, 2006

GSK And Sirna In Respiratory Pact

Drug development deal highlights growing interest in RNAi technology
Department: Business

In the latest show of faith in the potential of gene-silencing technology, GlaxoSmithKline has teamed up with Sirna Therapeutics to develop RNA interference-based drugs to treat respiratory diseases.

GSK will make an initial payment of $12 million comprising cash and investment in Sirna stock. Sirna says it could rake in another $700 million in milestone payments and royalties on potential product sales.

Sirna will supply optimized and formulated short interfering RNAs against targets . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society